A multi-center, randomized, double-blind, parallel-group study evaluating the sexual functioning of healthy adults after receiving multiple-dose regimens of vilazodone, paroxetine, or placebo
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2016
Price : $35 *
At a glance
- Drugs Vilazodone (Primary) ; Paroxetine
- Indications Generalised anxiety disorder; Major depressive disorder; Sexual function disorders; Social phobia
- Focus Therapeutic Use
- Sponsors Actavis; Forest Laboratories
- 16 Sep 2016 Results published in the International Clinical Psychopharmacology
- 11 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Jul 2014 According to Actavis media release, Forest Laboratories was acquired by Actavis in Jul 2014.